Skip to main content
. Author manuscript; available in PMC: 2022 Jun 14.
Published in final edited form as: Cell Rep. 2022 May 24;39(8):110839. doi: 10.1016/j.celrep.2022.110839

Figure 1. Construction, characterization, and in vitro evaluation of anti-EGFR ADCs.

Figure 1.

(A) Preparation and electrospray ionization mass spectrometry (ESI-MS) analysis of homogeneous ADC 1. Top panel: N88A/N297A anti-EGFR mAb (cetuximab mutant). Middle panel: mAb-linker conjugate. Bottom panel: homogeneous ADC 1. Asterisk (*) indicates a fragment ion detected in ESI-MS analysis.

(B) Preparation and HIC analysis of Cys conjugate 2.

(C) Preparation and ESI-MS analysis of Lys conjugate 3.

(D and E) Cell-based ELISA in U87ΔEGFR-luc (EGFRvIII+) and HEK293 (EGFR−, EGFRvIII−) cells.

(F–H) Cell-killing potency in U87ΔEGFR-luc, Gli36δEGFR (EGFRvIII+), and HEK293 (mean values ± SEM, n = 3). Concentrations are based on the antibody dose without normalizing to each DAR.